Author: admin

San Diego Custom Painting Highlights Key Factors to Consider Before Starting a Cabinet Painting Project

San Diego Custom Painting Highlights Key Factors to Consider Before Starting a Cabinet Painting Project
San Diego Custom Painting is a premier painting company. In a recent update, the company highlighted key factors to consider before starting a cabinet painting project.

Spring Valley, CA – In a website post, San Diego Custom Painting highlighted key factors to consider before starting a cabinet painting project.

The professionals said that before diving into a cabinet painting Spring Valley project, it is essential to consider multiple crucial factors that can impact the final result. First and foremost is the importance of proper preparation. Cabinets need to be completely cleaned and sanded to remove any grease, grime, or old paint. Skipping this preparation can lead to peeling paint and an uneven finish.

The cabinet painters Spring Valley noted that another significant factor is the choice of paint. Not all paints are suitable for cabinets, which sustain lots of wear and tear in everyday use. Selecting high-quality, durable paint specifically designed for cabinetry or furniture is advisable. These paints usually have a hard, smooth finish that can withstand frequent cleaning and resist chipping. 

The technicians added that having a clear plan for the project timeline and space organization is crucial. Painting kitchen cabinets Spring Valley can be time-consuming, often requiring several coats of paint and ample drying time between each coat. Ensuring enough time is allocated to complete the project without rushing will result in a better finish. Additionally, organizing the workspace efficiently can help keep the project on track and prevent any mix-ups. 

About San Diego Custom Painting

San Diego Custom Painting is a leading painting company. The team comprises skilled professionals who are passionate about their craft. Their expertise extends beyond basic painting to include intricate design elements and meticulous surface preparation, ensuring every job meets the highest standards. The firm’s reputation for reliability and excellence is built on a foundation of trust and satisfied clients who appreciate the transformative power of expertly applied paint.

San Diego Custom Painting

9413 Cape Cod Ct, Spring Valley, CA 91977

(619) 464-4030

Media Contact
Company Name: San Diego Custom Painting
Contact Person: Emily Escalante
Email: Send Email
Phone: (619) 464-4030
City: Spring Valley
State: California
Country: United States
Website: https://sdcustompainting.com/

Netpower Launches WordPress-Optimized VPS for Superior Performance and Security

Netpower has launched VPS optimized for WordPress, offering great performance, security, and scalability. These VPS feature advanced hardware for fast load times and reliable uptime. They come with strong security measures to protect your site, and they can grow with your business. Easy to set up and manage, they include 24/7 support from WordPress experts. Plus, they are eco-friendly and competitively priced. Perfect for any business looking to improve their WordPress hosting.

Netpower web hosting provider of managed WordPress hosting, comprehensive SEO services, and professional content writing, has announced the introduction of its new line of WordPress-optimized VPS. These VPS are designed to offer exceptional performance, security, and reliability, specifically tailored to meet the unique needs of WordPress users.

Advanced Technology for Unmatched Performance

Netpower WordPress-optimized VPS are built on cutting-edge hardware and infrastructure, ensuring optimal website performance. With features such as SSD storage, high-performance CPUs, and advanced caching mechanisms, these VPS guarantee lightning-fast load times and impressive uptime. This ensures that WordPress sites remain responsive and accessible, even during peak traffic times.

Robust Security Measures

Security is a core focus for Netpower, and the new VPS are equipped with comprehensive security features to protect WordPress sites from various threats. These include automated malware scanning, DDoS protection, and regular security updates. Additionally, Netpower’s expert team constantly monitors the VPS for potential vulnerabilities, providing clients with peace of mind regarding their data security.

Scalable Solutions for Growing Businesses

Recognizing the evolving needs of growing businesses, Netpower WordPress-optimized VPS offer scalable solutions that can easily adapt to increasing demands. Whether it’s a small blog or a large e-commerce site, these flexible hosting plans accommodate increased traffic and resource requirements without compromising performance.

Easy Integration and Management

The transition to Netpower WordPress-optimized VPS is seamless, with a dedicated support team assisting with migration to ensure minimal downtime and no data loss. Post-migration, managing the hosting environment is straightforward, thanks to a user-friendly control panel that allows for easy management of domains, emails, databases, and more from a central location.

24/7 Expert Support

Netpower managed WordPress hosting is known for its exceptional customer support. A team of WordPress experts is available around the clock to assist with any hosting-related issues or questions. From server configuration to troubleshooting and website optimization, the support team provides comprehensive assistance at every step.

Enhanced SEO Capabilities

The VPS are configured to support the latest SEO best practices, helping websites achieve higher search engine rankings. Fast load times, secure connections, and reliable uptime are critical factors for SEO, and Netpower WordPress-optimized VPS are designed to meet these requirements effectively.

Transparent and Competitive Pricing

Netpower offers competitive pricing for its WordPress-optimized VPS, ensuring high-quality hosting is accessible to businesses of all sizes. The transparent pricing structure means no hidden fees or surprise charges, with various plans available to suit different budgets and needs.

Commitment to Sustainability

Netpower is dedicated to sustainability, utilizing energy-efficient technologies and renewable energy sources in its data centers to minimize environmental impact. Clients choosing Netpower’s WordPress-optimized VPS are supporting environmentally responsible practices while benefiting from reliable hosting solutions.

Join the Netpower Community

The new WordPress-optimized VPS from Netpower provide high-performance, secure, and scalable hosting solutions for WordPress sites. Businesses looking to enhance their online presence can join the growing community of satisfied Netpower clients. More information about the VPS and available plans can be found on Netpower website at https://www.netpower.co.il

About Netpower

Established in 2011, Netpower has become a leader in managed WordPress hosting, SEO services, and professional content writing. The company’s mission is to empower businesses with reliable and high-performance hosting solutions, enabling them to achieve their online objectives. With a focus on innovation and customer satisfaction, Netpower continues to set industry standards for excellence.

Media Contact
Company Name: netpower ltd
Contact Person: Netanel Siboni
Email: Send Email
City: Afula
Country: Israel
Website: www.netpower.co.il

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Netpower Launches WordPress-Optimized VPS for Superior Performance and Security

Lost Vegas Fun Casino Hire Celebrates Twentieth Anniversary And International Tour

UK based Lost Vegas Casino Hire are celebrating their twentieth anniversary alongside international tour.

Founded by Catherine Harrington and her father in 2004, Lost Vegas supplies high-end fun casino equipment and professional Mayfair croupiers to weddings, private events and corporate clients around the world.

Over the years, Lost Vegas have become a prominent player in the UK events industry with many television set appearances including Downton Abbey, celebrity clients, and brands including Dior, F1, Amazon, Moet and Lotus. 

Catherine Harrington, Co-Founder of Lost Vegas, said: “People come to us because they’re looking for a fun and exciting experience, not just casino tables. We all thrive on creating a unique interactive experience for our clients and their guests and are renowned for the best ‘fun casino’ set up in the Southeast England.

“Our croupier team is extremely experienced with impressive resumes including The Ritz and Crockfords to enhance event experience to surprise and delight guests. We also use the best fully sized equipment, which you do not find at events often.

“We love working on a wide variety of events and have been so fortunate over the years to work with an incredible line up of clients, including many celebrity events, cruise ships and even film sets!” 


Video Link: https://www.youtube.com/embed/4NIpRJ37PRI

The company were recently chosen to send a crew to a high-profile event in Jamnagar, India, based on the reputation of their world-class highly trained Mayfair croupiers.

Harrington continued: “Lost Vegas were recently selected for their reputation of the most talented highly trained fun casino event croupiers in the world to send a record number of professional crew to a high-profile pre-wedding event in Jamnagar, India for the richest family in Asia.

“The 3-day event captivated audiences around the world with the world’s rich and famous pictured at the bash. Attended by Heads of State, Bollywood Royalty, Celebrities, tech billionaires, sports superstars.

“More than 1,000 guests were amazed and entertained by Rhianna, Famous Bollywood Stars, David Blaine and Cirque du Soliel as well as witnessing the world’s largest drone show. At this multi-million-dollar event, Lost Vegas were privileged to have worked alongside these entertainers and India’s leading five-star hotel group who created over five hundred dishes.” 

Lost Vegas are also recommended suppliers at prestigious UK venues including the Savoy Hotel in London and hold a perfect 5 stars on Google reviews

For more information on the company please go to www.lost-vegas.co.uk

Media Contact
Company Name: Kerri L Watt Media
Contact Person: Kerri L Watt
Email: Send Email
Phone: +44 7934 877 206
Country: United Kingdom
Website: http://www.kerrilwatt.co.uk

Empty Capsules Market Size, Opportunities, Top Companies, Growth, Trends, Key Segments, Regional Graph and Forecast to 2029

“Key players in the empty capsules market include Capsugel (Lonza) (Switzerland), ACG (India), QUALICAPS (Roquette Frères) (France), SUHEUNG (South Korea), Shanxi Guangsheng Capsule Limited (China), CapsCanada (Lyfe Group) (US)”
Browse 356 market data Tables and 48 Figures spread through 333 Pages and in-depth TOC on “Empty Capsules Market by Type (Gelatin (Porcine, Bovine, Bonemeal), Non-gelatin (HPMC, Starch)), Functionality (Immediate-release, Sustained-Release, Delayed-release),Therapeutic Application (Antibiotic, Dietary, Antacid, CVD) – Global Forecast to 2029

The report “Empty Capsules Market by Type (Gelatin (Porcine, Bovine, Bonemeal), Non-gelatin (HPMC, Starch)), Functionality (Immediate-release, Sustained-Release, Delayed-release),Therapeutic Application (Antibiotic, Dietary, Antacid, CVD) – Global Forecast to 2029“, is projected to reach USD 4.2 billion by 2029 from an estimated USD 3.1 billion in 2024, at a CAGR of 6.3% during the forecast period. Expansion of the Over-the-counter medications, increasing demand for nutraceuticals, and benefits of capsules over other dosage forms are the major driving factors of the empty capsules market. However, issues related to the safety and side effects of gelatin capsules and cultural practices and dietary restrictions are the major restraining factors of the empty capsules market.

Browse 356 market data Tables and 48 Figures spread through 333 Pages and in-depth TOC on “Empty Capsules Market by Type (Gelatin (Porcine, Bovine, Bonemeal), Non-gelatin (HPMC, Starch)), Functionality (Immediate-release, Sustained-Release, Delayed-release),Therapeutic Application (Antibiotic, Dietary, Antacid, CVD) – Global Forecast to 2029″View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html

Empty Capsules Market

The gelatin capsules segment accounted for the largest share by type in the empty capsules market in 2023.

By type, the empty capsules market has been further categorized as gelatin capsules and non-gelatin capsules. The gelatin capsules segment is further sub-segmented into porcine gelatin, bovine-derived gelatin, bone meal, and other gelatin sources. The non-gelatin segment is further categorized as including hydroxypropyl methylcellulose (HPMC) capsules and pullulan & starch capsules. The gelatin segment accounted for the largest share of the market in 2023 due to their excellent biocompatibility and ability to effectively encapsulate a wide range of active ingredients, making them a preferred choice in pharmaceuticals and nutraceuticals. Furthermore, their ease of production and cost-effectiveness enhance their appeal in these industries.

The immediate-release capsules segment is expected to grow at a higher rate during the forecast period.

Based on functionality, the empty capsules market has been segmented into immediate-release capsules, sustained-release capsules, and delayed-release capsules. In 2023, the immediate-release capsules segment accounted for the largest share of the empty capsules market and is expected to grow at a higher growth rate during the forecast period of 2024-2029. The immediate-release empty capsules can provide a rapid onset of action, which is crucial for treating acute conditions, and their widespread use in over-the-counter and prescription medications is expected to drive the segment during the forecast period. Additionally, their compatibility with various drug formulations and cost-effective production further boost their market demand.

The antibiotic & antibacterial drugs segment accounted for the largest share of the therapeutic application segment in the empty capsules market

Based on therapeutic application, the empty capsules market has been segmented into antibiotic & antibacterial drugs, dietary supplements, antacid & antiflatulent preparations, antianemic preparations, anti-inflammatory drugs, cardiovascular therapy drugs, cough & cold drugs, other therapeutic applications. In 2023, the antibiotic & antibacterial drugs segment accounted for the largest share of the empty capsules market. Antibiotic and antibacterial drugs can protect sensitive active ingredients from degradation, ensuring optimal efficacy and their suitability for precise dosing, facilitating accurate administration; these factors are expected to drive the segment’s growth. Additionally, the rising incidence of bacterial infections and the need for effective and convenient treatment options contribute to their market demand.

The North American region accounted for the largest share of the empty capsules market in 2023.

The empty capsules market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. North America region accounted for the largest share of the global empty capsules market in 2023. Factors such as increasing consumer awareness of health and wellness and a growing preference for dietary supplements have contributed to the market’s growth. However, the empty capsules market in the Asia Pacific region is expected to grow at a higher rate during 2024-2029. The growth of the empty capsules market in Asia Pacific is driven by the rising demand for dietary supplements, the increasing prevalence of chronic diseases, and the expansion of the pharmaceutical industry. Additionally, advancements in capsule delivery technologies and a growing preference for capsule-based drug delivery systems contribute to market expansion.

Key players in the empty capsules market include Capsugel (Lonza) (Switzerland), ACG (India), QUALICAPS (Roquette Frères) (France), SUHEUNG (South Korea), Shanxi Guangsheng Capsule Limited (China), CapsCanada (Lyfe Group) (US), HealthCaps India (India), Nectar Lifesciences Ltd. (India), Sunil Healthcare Limited (India), Farmacápsulas (Colombia), NATURAL CAPSULES LIMITED (India), Erawat Pharma Limited (India), Qingdao Yiqing Biotechnology Co., Ltd. (Baotou Dongbao Bio-Tech Co., Ltd.) (China), Fortcaps ( Kumar Organic Products Limited) (India), Comed Chemicals Limited (India), Roxlor (US), Medisca Inc. (US), Zhejiang Yuexi Capsule Co. (China), ZHEJIANG HUILI CAPSULES CO., LTD (China), Shaoxing Zhongya Capsule Co., Ltd. (China), Shing Lih Fang Enterprise Co., Ltd. (Taiwan), Chemcaps Limited (India), SNAIL PHARMA INDUSTRY (China), SavoiurCaps (India), Shanxi JC Biological Technology CO. (China), Shaoxing Kangke Capsule Co., Ltd. (China), Lefancaps (Canada), BIO-CAPS INDIA LTD. (India), BioCaps Enterprise (US), Bright Pharma Caps (US), and SHREE PHARMA CAPS (India).

Don’t miss out on business opportunities in Empty Capsules Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarketsblog.com/empty-capsules-market-trends-drivers-and-future-opportunities.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Empty Capsules Market Size, Opportunities, Top Companies, Growth, Trends, Key Segments, Regional Graph and Forecast to 2029

Ball Valves Market worth $17.0 billion by 2028, at a CAGR of 4.6%

“Ball Valves Market”
The global Ball Valves Market in terms of revenue was estimated to be worth $13.6 billion in 2023 and is poised to reach $17.0 billion by 2028, growing at a CAGR of 4.6% during the forecast period.

The report “Ball Valves Market by Material (Cast Iron, Stainless Steel, Alloy-based, Brass, Bronze & Plastic), Type(Trunnion-mounted, Floating, Rising Stem), Size (<1”, 1”-5”, 6”-24”, 25”-50” & >50”), Industry (Oil & Gas, Chemicals) & Region – Global Forecast to 2028” The global Ball valves industry size is expected to grow from USD 13.6 billion in 2023 to USD 17.0 billion by 2028, registering a CAGR of 4.6%. The ball valves market has witnessed significant growth attributed to increased industrialization, amplified demands from the oil & gas sector, water treatment, and expanding global infrastructure projects. Technological advancements and a focus on efficient fluid control systems have propelled this expansion.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80882742

Browse 218 market data Tables and 59 Figures spread through 240 Pages and in-depth TOC on “Ball Valves Market by Material (Cast Iron, Stainless Steel, Alloy-based, Brass, Bronze & Plastic), Type(Trunnion-mounted, Floating, Rising Stem), Size (<1”, 1”-5”, 6”-24”, 25”-50” & >50”), Industry (Oil & Gas, Chemicals) & Region – Global Forecast to 2028”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/ball-valve-market-80882742.html

Ball Valves Market

By segment, ball valves industry for Stainless steel to hold the largest market share in the year 2022.

The global market for stainless steel ball valves has seen significant expansion owing to their enduring nature, resistance to corrosion, and versatility across industries like oil & gas, chemicals, and water treatment. Their reliability has driven heightened demand, establishing them as a crucial component in numerous sectors worldwide.

By segment, ball valves industry for Trunnion-mounted to record the highest CAGR during the forecast period.

The evolution of Trunnion Mounted Ball Valves has surged owing to their resilient construction, guaranteeing steadfast functionality in high-pressure settings across diverse sectors such as oil and gas, petrochemicals, and power generation. Their reinforced sealing, enduring nature, and capacity to manage demanding environments have sparked heightened acceptance, delivered effective fluid regulation while mitigated potential leakage hazards in pivotal operations.

By segment, ball valves industry for 1”-5” segment to record the highest CAGR during the forecast period.

The growth trajectory of ball valves spanning sizes from 1”-5” has surged remarkably, propelled by their versatile utility across diverse industries. These valves are prized for their adeptness in managing fluid flow, ensuring reliable seals, and exhibiting robust durability. Widely embraced in sectors like oil, gas, water treatment, and chemical processing, their compact design, capacity to withstand high pressures, and ease of maintenance continue to fuel escalating demand in industrial applications.

By segment, ball valves industry for pulp & paper segment to record the highest CAGR during the forecast period.

Ball valves are pivotal in the Pulp & Paper industry for their reliability and durability in corrosive pulp processes. Withstanding harsh chemicals and high pressures, they ensure tight seals, preventing leaks critical in pulp production. As the industry seeks efficiency and reduced downtime, ball valves play a vital role, promoting continuous growth and innovation to meet evolving operational demands.

By region, ball valves industry in Asia Pacific is expected to grow at the highest CAGR from 2023 to 2028.

The Asia Pacific area has experienced a notable surge in ball valve adoption owing to its robustness, reliability, and effectiveness across industries like oil & gas, water treatment, and manufacturing. This increased usage is a result of the region’s burgeoning infrastructure development and urbanization trends. Consequently, it has sparked substantial market growth, paving the way for pioneering advancements in valve technology within the region.

Key players operating in the Ball valves industry include Emerson Electric Co. (US), Flowserve Corporation (US), SLB (US), IMI (UK), Valmet (Finland), Crane Company (US), KITZ Corporation (Japan), Neway Valves Co. Ltd. (China), Spirax Sarco Limited (UK), Trillium Flow Technologies (US) and Others in the Ball valves industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ball-valve-market-80882742.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ball Valves Market worth $17.0 billion by 2028, at a CAGR of 4.6%

Bruce Beryl Fisher’s New Book is a Pulse Pounding Tale of an 18-year-old Schoolboy, His Struggle with Dyslexia, and an Unprecedented Love Story

“Taking the Short Bus” is a masterpiece from Bruce Beryl Fisher and it follows the story of Eric who battles with dyslexia at a time when the acceptance of learning disabilities wasn’t as widespread as today

Bruce Beryl Fisher is pleased to announce that work is complete on his book, “Taking The Short Bus,” and it has been released. Taking the Short Bus is a gripping, comedy novel that follows the life and struggles of Eric Blum, an 18-year-old with dyslexia attending Noah Webster Preparatory. Several points make this book stand out, and one such point is the book’s setting. Bruce takes the reader back to the time just before the Disco era, after the Vietnam War, mid 70s.

One of the many woes that befell Eric was losing his brother in the war. Having dyslexia also spelled more challenges for Eric as during this time, people with learning disabilities weren’t cut as much slack as they now get today. This meant that Eric had more than just dyslexia to deal with – he had to struggle through the prevalent societal reservations about people with his condition.

Notwithstanding, Eric endeavors to prove to the school that he is qualified to graduate which he does, and then proceeds to go to college. In an unprecedented turn of events, Eric falls in love with his history teacher, Carol Schor.

The book is a dynamic journey through a love story and Eric’s personal struggles, shedding light on individuals with learning disabilities. Through vivid storytelling, Bruce Beryl Fisher captures the essence of Eric’s journey, inspiring readers to embrace their true potential, and challenging the status quo.

A must-read for anyone seeking inspiration, it reminds us that love and tenacity can prevail in the face of adversity. “Taking the Short Bus is now available on Amazon. To get it, please visit https://www.amazon.com/Taking-Short-Bus-Teacher-Need/dp/B0CS27GV8N/ref=monarch_sidesheet.

About Bruce Beryl Fisher

Bruce Beryl Fisher was born in Philadelphia. Being subjected to the abomination of the Philadelphia school system motivated him to write this novel. Once a studio manager for Whitney Houston, Cyndi Lauper, and the Bee Gees.

Bruce is now retired after working as a stagehand with the International Alliance of Theater Stage Employees (IATSE Local 500) in Miami Florida. He currently resides in Hollywood Florida with his wife and son.

Media Contact
Company Name: Bruce Beryl Fisher
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: www.bruceberylfisher.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bruce Beryl Fisher’s New Book is a Pulse Pounding Tale of an 18-year-old Schoolboy, His Struggle with Dyslexia, and an Unprecedented Love Story

Hypertension Pipeline 2024 | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis,

DelveInsight, “Hypertension Pipeline Insight 2024” report provides comprehensive insights about 100+ Hypertension companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from Hypertension Pipeline Report

  • July 2024:- Mineralys Therapeutics Inc.- This study is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications, one of which must be a thiazide or thiazide-like diuretic. A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension.
  • July 2024:- Alnylam Pharmaceuticals- A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension. The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
  • DelveInsight’s Hypertension pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
  • The leading companies working in the Hypertension Market include Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
  • Promising Hypertension Pipeline Therapies in the various stages of development include Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.

 

Request a sample and discover the recent advances in Hypertension Treatment Drugs @ Hypertension Pipeline Report

 

In the Hypertension pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Hypertension Overview

Hypertension is the most common primary diagnosis in the United States. It affects approximately 86 million adults (≥20 years) in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication.

 

Find out more about Hypertension Therapeutics Assessment @ Hypertension Preclinical and Discovery Stage Products

 

Hypertension Emerging Drugs Profile

  • Firibastat: Quantum Genomics
  • Baxdrostat (CIN-107): CinCor Pharma
  • MLS-101: Mineralys Therapeutics
  • Zilebesiran (ALN-AGT): Alnylam Therapeutics
  • IONIS-AGT-LRx: Ionis Pharmaceuticals 

 

Hypertension Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Hypertension therapies. The Hypertension companies which have their Hypertension drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.

 

DelveInsight’s Hypertension pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Hypertension Pipeline Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Learn more about the emerging Hypertension Pipeline Therapies @ Hypertension Clinical Trials Assessment

 

Scope of the Hypertension Pipeline Report

  • Coverage- Global
  • Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Hypertension Companies- Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
  • Hypertension Pipeline Therapies- Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.

 

Dive deep into rich insights for new drugs for Hypertension Treatment, Visit @ Hypertension Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hypertension: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hypertension – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Firibastat: Quantum Genomics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Baxdrostat (CIN-107): CinCor Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ID-140009: IlDong Pharmaceutical
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. CKD 331: Chong Kun Dang
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hypertension Key Companies
  21. Hypertension Key Products
  22. Hypertension- Unmet Needs
  23. Hypertension- Market Drivers and Barriers
  24. Hypertension- Future Perspectives and Conclusion
  25. Hypertension Analyst Views
  26. Hypertension Key Companies
  27. Appendix

 

For further information on the Hypertension Pipeline therapeutics, reach out to Hypertension Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypertension Pipeline 2024 | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis,

Hepatocellular Carcinoma Pipeline 2024 | Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma

DelveInsight, “Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

  • DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
  • The leading companies working in the Hepatocellular Carcinoma Market include Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
  • Promising Hepatocellular Carcinoma Pipeline Therapies in the various stages of development include lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.

 

Request a sample and discover the recent advances in Hepatocellular Carcinoma Treatment Drugs @ Hepatocellular Carcinoma Pipeline Outlook

 

In the Hepatocellular Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV.

 

Find out more about Hepatocellular Carcinoma Treatment Landscape @ Drugs for Hepatocellular Carcinoma Treatment

 

Hepatocellular Carcinoma Emerging Drugs Profile

  • Namodenoson: Can-Fite BioPharma
  • SRF388: Surface Oncology
  • Porustobart: Harbour BioMed
  • Fisogatinib: CStone Pharmaceuticals
  • STP705: Sirnaomics

 

Hepatocellular Carcinoma Pipeline Therapeutics Assessment

There are approx. 90+ key Hepatocellular Carcinoma companies which are developing the therapies for Hepatocellular Carcinoma. The Hepatocellular Carcinoma companies which have their Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.

 

DelveInsight’s Hepatocellular Carcinoma Pipeline Report covers around 95+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Hepatocellular Carcinoma Pipeline Therapies @ Hepatocellular Carcinoma Clinical Trials Assessment

 

Scope of the Hepatocellular Carcinoma Pipeline Report

  • Coverage- Global
  • Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
  • Hepatocellular Carcinoma Pipeline Therapies- lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others. 

 

Dive deep into rich insights for new drugs for Hepatocellular Carcinoma Treatment, Visit @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatocellular Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Namodenoson: Can-Fite BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SRF388: Surface Oncology
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. STP705: Sirnaomics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hepatocellular Carcinoma Key Companies
  21. Hepatocellular Carcinoma Key Products
  22. Hepatocellular Carcinoma- Unmet Needs
  23. Hepatocellular Carcinoma- Market Drivers and Barriers
  24. Hepatocellular Carcinoma- Future Perspectives and Conclusion
  25. Hepatocellular Carcinoma Analyst Views
  26. Hepatocellular Carcinoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Pipeline 2024 | Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma

Hepatitis B Virus Infection Pipeline 2024 | Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences

DelveInsight, “Hepatitis B Virus Infection Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Hepatitis B Virus Infection Pipeline Report

  • July 2024:- GlaxoSmithKline– A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment. This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with Human Immunodeficiency Virus (HIV)/Hepatitis B Virus (HBV) co-infection.
  • July 2024:- Gilead Sciences– A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
  • DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
  • The leading companies working in the Hepatitis B Virus Infection Market include Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
  • Promising Hepatitis B Virus Infection Pipeline Therapies in the various stages of development include BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.

 

Request a sample and discover the recent advances in Hepatitis B Virus Infection Treatment Drugs @ Hepatitis B Virus Infection Pipeline Report

 

In the Hepatitis B Virus Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Hepatitis B Virus Infection Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids. Oral-fecal transmission is possible but considerably rare.

 

Find out more about Hepatitis B Virus Infection Therapeutics Assessment @ Hepatitis B Virus Infection Preclinical and Discovery Stage Products

 

 Hepatitis B Virus Infection Emerging Drugs Profile

  • Bepirovirsen: GSK
  • VIR 2218: Vir Biotechnology
  • AB 729: Arbutus Biopharma
  • AHB-137: Ausper Biopharma

 

Hepatitis B Virus Infection Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the Hepatitis B Virus Infection. The Hepatitis B Virus Infection companies which have their Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. phase III include GSK.

 

DelveInsight’s Hepatitis B Virus Infection pipeline report covers around 90+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Hepatitis B Virus Infection Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Hepatitis B Virus Infection Pipeline Therapies @ Hepatitis B Virus Infection Clinical Trials Assessment

 

Scope of the Hepatitis B Virus Infection Pipeline Report

  • Coverage- Global
  • Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
  • Hepatitis B Virus Infection Pipeline Therapies- BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.

 

Dive deep into rich insights for new drugs for Hepatitis B Virus Infection Treatment, Visit @ Hepatitis B Virus Infection Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatitis B Virus Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Bepirovirsen: GSK
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. VIR 2218: Vir Biotechnology
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AHB-137: Ausper Biopharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hepatitis B Virus Infection Key Companies
  21. Hepatitis B Virus Infection Key Products
  22. Hepatitis B Virus Infection- Unmet Needs
  23. Hepatitis B Virus Infection- Market Drivers and Barriers
  24. Hepatitis B Virus Infection- Future Perspectives and Conclusion
  25. Hepatitis B Virus Infection Analyst Views
  26. Hepatitis B Virus Infection Key Companies
  27. Appendix

 

For further information on the Hepatitis B Virus Infection Pipeline therapeutics, reach out to Hepatitis B Virus Infection Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis B Virus Infection Pipeline 2024 | Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences

Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma

DelveInsight’s, “Osteoarthritis Pipeline Insight 2024” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request a sample and discover the recent advances in Osteoarthritis treatment drugs @ Osteoarthritis Pipeline Outlook

 

Key Takeaways from the Osteoarthritis Pipeline Report

  • June 2024:- New Approaches to Neuroblastoma Therapy Consortium- Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial. This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
  • DelveInsight’s Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
  • The leading Osteoarthritis Companies working in the market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
  • Promising Osteoarthritis Therapies in the various stages of development include E1K 1,200 ㎍joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.

 

 Find out more about Osteoarthritis treatment drugs @ Drugs for Osteoarthritis Treatment

 

Osteoarthritis Emerging Drugs Profile

  • Lorecivivint: Biosplice Therapeutics
  • CYP 004: Cynata Therapeutics
  • JTA-004: Bone Therapeutics
  • SMUP-IA-01: Medipost
  • TTAX03: Tissue Tech 

 

Osteoarthritis Therapeutics Assessment

There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.

 

DelveInsight’s Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Osteoarthritis pipeline therapies @ Osteoarthritis Clinical Trials

 

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous

 

Osteoarthritis Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Osteoarthritis Companies

Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.

 

Dive deep into rich insights for new drugs for Osteoarthritis Treatment, visit @ New Osteoarthritis Drugs

 

Scope of the Osteoarthritis Pipeline Report

  • Coverage- Global
  • Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
  • Osteoarthritis Therapies- E1K 1,200 ㎍/joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.

 

For further information on the Osteoarthritis Pipeline Therapeutics, reach out @ Osteoarthritis Treatment Drugs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Osteoarthritis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Osteoarthritis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lorecivivint: Biosplice Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TTAX03: Tissue Tech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. GLPG-0555: Gilead Sciences
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Protego-PD: Plakous Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Osteoarthritis Key Companies
  21. Osteoarthritis Key Products
  22. Osteoarthritis- Unmet Needs
  23. Osteoarthritis- Market Drivers and Barriers
  24. Osteoarthritis- Future Perspectives and Conclusion
  25. Osteoarthritis Analyst Views
  26. Osteoarthritis Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma